Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST). This approval extends to both adult and pediatric patients aged two years and older. Promacta’s New FDA Approval: Enhancing […]